Valued at USD 3 billion in 2025, the sector is currently dominated by the United States, which accounts for approximately 40% of the global market share among the seven major markets (7MM). Growth is underpinned by the rising incidence of ALK-positive non-small cell lung cancer and an increased clinical emphasis on controlling brain metastases, a common complication that requires drugs capable of crossing the blood-brain barrier.

Innovation is shifting toward next-generation candidates such as Neladalkib (NVL-655) from Nuvalent, TRI-611 by TRIANA Biomedicines, and APG-2449 from Ascentage Pharma. These therapies move beyond first-generation inhibitors like Crizotinib, aiming to tackle compound resistance mutations that historically limited treatment duration. As diagnostic techniques like next-generation sequencing become standard, clinicians are better positioned to match patients with these specialized treatments, setting a trajectory for a 4% compound annual growth rate over the next decade.